@MidwesternDoc One company actually tried to bring UVBI back. Vasogen raised $225 million, completed more than 60 studies, and showed very strong results in Phase II trials for heart failure and vascular disease. Their version wasn’t even as effective as classic UVBI, yet it still worked!